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ABSTRACT 
Aim: Biological valves are the most commonly implanted prostheses for aortic valve replacement 
(AVR) surgery in the United Kingdom. The aim of this study was to compare performance of porcine 
and bovine pericardial valves implanted in AVR surgery with respect to survival and intervention-free 
survival in a retrospective observational study. 
Methods: Prospectively collected clinical data for all first-time elective and urgent AVRs with or 
without concomitant coronary artery bypass graft (CABG) surgery performed in England and Wales 
between April-2003 and March-2013 were extracted from the National Institute for Cardiovascular 
Outcomes database. Patient life-status was tracked from the Office for National Statistics. Time-to-
event analyses were performed using log-rank tests and Cox proportional hazards regression 
modelling with grouped frailty for responsible cardiac surgeons.  
Results: A total of 38,040 patients were included (64.9% bovine pericardial; 35.1% porcine). Patient 
and characteristics were similar between the groups. Median follow-up was 3.6 years. There was no 
statistically significant difference in survival (P=0.767) (10-year survival was 49.0% and 50.3% in the 
bovine pericardial and porcine groups respectively) or intervention-free survival. The adjusted hazard 
ratio for porcine valves was 0.98 [95%CI 0.93-1.03]. Sensitivity analysis in small valve sizes showed 
no difference in intervention-free survival. There was some evidence of a protective effect for porcine 
valves in relatively younger patients (P=0.074). 
Conclusion: There were no differences in intervention free survival between bovine pericardial and 
porcine valves used in first-time AVR ± CABG up to a maximum of 10 years.  
 
Keywords: aortic valve replacement; porcine; bovine pericardial; outcomes 
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INTRODUCTION 
Biological prosthetic valves are a standard choice of implant for aortic valve replacement 
(AVR) in older patients, as they do not require the patient to take a lifelong regime of anticoagulation 
medication, negating the associated complications. There has also been a shift towards biological 
valve implantation in relatively younger patients reported.1 Between 2004 and 2008, 21,360 out of 
30,443 (70.2%) implanted prostheses were reported as being biological.2 The most frequently 
implanted biological valves are either porcine xenograft valves or bovine pericardial tissue valves. 
These valves have been extensively studied since their first use in the 1960s and 70s because they 
suffer calcification and structural deterioration, in addition to standard valve replacement 
complications such as thromboembolic events; endocarditis; and patient-prosthesis mismatch. To 
date, the evidence base of outcomes for these valves is based on a series of relatively small-
randomised studies and some larger non-randomised case series. The data on comparative outcomes is 
inconclusive with some reported benefits in haemodynamic and complication endpoints, but no 
differences in survival.3  
The largest study to date contains fewer than 2000 valves of any one type, which would be 
unlikely to pick up small but important differences in late outcomes. The aim of this study is to 
compare the performance of prosthetic porcine xenograft and bovine pericardial valves implanted in 
aortic valve replacement surgery with respect to in-hospital mortality, mid-term survival and 
intervention-free survival on a large cohort using 10-years of national registry data collected in 
hospitals in England and Wales.  
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MATERIALS AND METHODS 
Data extraction and pre-processing 
Prospectively collected data were extracted from The National Institute for Cardiovascular 
Outcomes Research (NICOR) National Adult Cardiac Surgery Audit (NACSA) registry (version 
4.1.2) on 14th January 2014 for all adult cardiac surgery procedures performed in the United 
Kingdom. As described elsewhere, reproducible cleaning algorithms were applied to the database.4 
Briefly, duplicate records and non-adult cardiac surgery entries (including transcatheter aortic valve 
implantations [TAVIs]) were removed; transcriptional discrepancies harmonised; and clinical and 
temporal conflicts and extreme values corrected or removed. The data is returned regularly to each 
unit for local validation as part of the National Adult Cardiac Surgery Audit in the United Kingdom.2  
For this study, records were included if they corresponded to either an isolated AVR or AVR 
+ CABG operation, with a bio-prosthetic implant performed in England and Wales between 1st April 
2003 and 31st March 2013. No other concomitant surgery was included. Exclusion criteria for this 
study were: 1) evidence of previous cardiac surgery; 2) emergency or salvage operation; 3) missing 
data for the responsible consultant cardiac surgeon; 4) data on discharge status or postoperative 
follow-up were missing. 
Study and outcome variables 
For each operation, data are recorded on patient characteristics, comorbidities, surgical team, 
intra-operative factors, and post-operative outcomes. For this study we extracted data on patient age at 
time of operation (years); gender; body mass index (BMI; defined as weight [kg] / height2 [m2]); 
operative urgency; dyspnoea (NYHA grade); history of neurological dysfunction; diabetes (diet or 
insulin controlled); history of hypertension; pulmonary hypertension (defined as a PA systolic 
pressure >60 mmHg); recent myocardial infarction (defined as within 90-days of surgery); serum 
creatinine >200 µmol/l; history of pulmonary disease; extracardiac arteriopathy; left ventricular 
ejection fraction (classified as <30%, 30-50%, and >50%); critical preoperative state (defined as per 
6	
	
the EuroSCORE group); use of preoperative IV nitrates; concomitant CABG; haemodynamics; active 
infective endocarditis.  
Administrative data was also extracted including: patient admission, procedure and discharge 
dates, and responsible consultant cardiac surgeon. Valve data extracted from the registry were valve 
name, model and size (mm). Names and model are recorded in the registry as free-text fields. For 
each record we also calculated the logistic EuroSCORE. Further details of variable definitions are 
available at http://www.ucl.ac.uk/nicor/audits/adultcardiacsurgery/datasets.  
The outcomes for this study were 1) in-hospital mortality, defined as death due to any cause 
during admission to the base hospital for cardiac surgery; 2) mid-term survival from all-cause 
mortality; and 3) intervention-free mid-term survival. Patients who died in-hospital on the day of 
surgery were recorded as having a nominal survival time of 0.5 days. Follow-up data up until the 
point of discharge was collected by the NACSA clinical registry system and post-discharge survival 
data was collected by linking the records via patient NHS numbers to the Office for National Statistics 
(ONS) death registry, which records all deaths in England and Wales. Data on cause of death was 
unavailable. An attempt to back-fill missing in-hospital mortality data was made by record linkage to 
the ONS registry.  
A re-intervention was defined as any surgery on the aortic valve in a separate subsequent 
admission spell, regardless of urgency or any concomitant surgery, performed up to the 31st March 
2013. As the NACSA registry is a procedural database, i.e. each operation receives its own separate 
entry; re-intervention was determined by identifying patients in the study according to their unique 
National Health Service (NHS) number who reappeared in the National Adult Cardiac Surgery Audit 
registry with evidence of aortic valve surgery. The time between the first and second operation on the 
aortic valve defines the time-to-event.  
Valve classification 
Valve type (bovine pericardial or porcine) is not explicitly recorded in the adult cardiac 
surgery registry. Instead, an algorithm was written that maps each recorded free-text name and model 
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to a homogenous list of known prosthetic valves. This list was developed from studying manufacturer 
catalogues; directly contacting valve companies; and using the Society of Thoracic Surgeons 
definitions file (http://www.sts.org/sites/default/files/documents/ValveDevices20140117.txt; last 
accessed 13 March 2014). Some hospitals used an internal coding system, and these units were 
contacted directly for the coding system. For each record, we recorded the valve manufacturer, model, 
series and (xeno-) type. Not all valves could be classified at the model level, for example “Edwards 
Lifesciences Perimount” could be one of a number of specific valves. In such a situation we could still 
identify the valve manufacturer, series and (xeno-) type, which was sufficient for this study. For each 
record, the number of matches to the list of known valves was recorded. 
After running this algorithm, a record was excluded if: 1) the valve name / model was missing 
or completely unidentifiable to the manufacturer level; 2) it was over-matched to more than one 
manufacturer, series, model or xenotype; 3) no match to a (xeno-) type could be made. In addition, 
any implants that were identified to be annuloplasty rings, valved conduits, or designed for use in the 
mitral position, were excluded from the analysis. As the focus of this study is in comparison of bovine 
pericardial and porcine valves, any bioprostheses identified as being any different type of xenograft 
(homografts, autografts or equine pericardium) were also excluded. No exclusion criteria on stented / 
stentless or sutured / sutureless was imposed as the purpose was only to compare material. 
As the UK valve market is dominated by five prosthetic heart valve manufactures (Edwards 
Lifesciences, Medtronic, St. Jude Medical, Sorin Group and Vascutek), we excluded three 
manufacturers with very small numbers of implants: Cryolife O’Brien, Shelhigh and Labcor.  
Statistical analysis 
Multiple imputation using chain equations was used to impute missing patient characteristic 
data and valve size.5 A total of 5 imputed data sets were generated. Variables included in the 
imputation models were all clinical and patient study variables in addition to valve model, valve size, 
year of operation and responsible consultant cardiac surgeon. 
8	
	
Categorical and dichotomous variables are summarised as absolute number and percentage. 
Continuous data are summarised as mean ± standard deviation (SD). Means of continuous variables 
were compared between groups using the independent samples t-test. Categorical and dichotomous 
variables were contrasted using the chi-square test. Due to the large sample size in each valve group, 
patient characteristics were also compared between bovine pericardial and porcine prostheses by 
means of standardised (bias) difference. A variable with absolute standardised difference of <10% 
supports the assumption of ‘balance’ between the two groups of patients.6 For each surgeon, the 
bovine pericardial prosthesis implantation rate is determined and compared to the total case volume. 
Time-to-event data are presented as Kaplan-Meier graphs stratified by xenotype, and 
compared using the log-rank test. To derive adjusted effects for xenotype, for each of the five imputed 
datasets, a Cox constant proportional hazards models with grouped frailty for the responsible 
consultant cardiac surgeons was fitted using a Gaussian distribution (with mean zero and standard 
deviation θ) for the random effects.7 All extracted patient demographics, comorbidities, and pre-
operative variables were included in the regression model. Valve type (bovine pericardial / porcine) 
was forced into the model. The logistic EuroSCORE was not entered into the model as we included 
most constituent risk factors separately. BMI was included as a quadratic polynomial term. Patient 
age was entered as piecewise linear polynomial with a single knot at 65 years; this specific modelling 
decision and knot selection was determined from examination of the smoothed martingale residual 
plot.8 The fixed effects for the five models are pooled according to Rubin’s rule and reported as 
hazard ratios with 95% confidence intervals.9  
Two supportive subgroup analyses were performed, each exclusively comparing differences 
in intervention-free survival. First, we estimated the univariable hazard ratio (taking into account the 
missing data by multiple imputation and combining the separate results, as per above) for valve type 
in the subset of patients implanted with a valve of size ≤21mm. Surgeon effects were adjusted for as 
per above. This is to examine whether any mid-term differences in intervention-free survival are 
detectable in the spectrum of valve sizes with known gradient differences between bovine pericardial 
and porcine prostheses. Second, we compared the valve types in patients aged <60 years, and 
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separately in patients aged ≥60 years at time of surgery, using a log-rank test for the first-imputed 
dataset only. Only 3 patients (<0.01%) had missing age data, therefore multiple imputation techniques 
were not applied. As a sensitivity analysis to this, an adjusted pooled hazard ratio was calculated.  
All analyses and data cleaning were performed in R version 3.0.3 (R Foundation for 
Statistical Computing, Vienna, Austria). Independent samples t-tests were used for comparison of 
means of continuous data. Multiple imputations were performed using the MICE package (version 
2.21). Frailty models were fitted using the R coxme package (version 2.2-3). In all cases, a P-value 
<0.05 was considered significant.  
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RESULTS 
Exploratory analyses   
From a total of 49,375 AVR ± CABG operations with bio-prosthetic implants performed in 
England and Wales over the 10-year study period, 38,040 patients were included in this study after 
applying the inclusion and exclusion criteria (Figure 1). In total 31 different valve classifications 
were included (Table 1): 24,695 bovine pericardial (64.9%) and 13,345 porcine (35.1%). The most 
frequently implanted bovine pericardial prosthesis was the Edwards Lifesciences Perimount 2900 
(24.5%; 6062 / 24,695). The most frequently implanted porcine valve was the Medtronic Mosaic 
(26.5%; 3534 / 13,345). Edwards Lifesciences made up the largest market share (56.7%).  
The numbers of missing data were low, with all patient variables having <2% missing data 
except for BMI (2.5%), pulmonary hypertension (10.1%), creatinine >200 µmol/l (5.4%), 
haemodynamics (2.8%), active infective endocarditis (6.9%). The patient characteristics between the 
bovine pericardial and porcine group were well balanced, as shown for the first imputed dataset 
(Table 2), consistent with a hypothesis that there is no treatment assignment selection bias. However, 
statistical tests of homogeneity did identify some variables as being significantly different; namely 
logistic EuroSCORE, age, gender, operative urgency, NYHA class, pulmonary hypertension, history 
of pulmonary disease, extracardiac arteriopathy, left ventricular function, preoperative IV nitrates, 
critical preoperative state, and valve haemodynamics. 
There was considerable scatter between total AVR ± CABG volume and the bovine 
pericardial implantation rate (Figure 2). However, there are clusters of surgeons who predominantly 
use bovine pericardial or porcine valves. Interestingly, low- and moderate-volume surgeons have a 
greater propensity to use bovine pericardial valves. The decision about whether to implant a bovine 
pericardial or porcine valve might be explained by a surgeon’s propensity to use one particular 
manufacturer, rather than a particular valve type. There were a large number of surgeons who 
predominantly implanted an Edwards Lifesciences valve. Edwards Lifesciences predominantly supply 
bovine pericardial valves. 
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The bovine pericardial implantation rate forms a distinctive u-shape: dipping in 2007-08 
(57.3%) before increasing again (73.2% at 2012-13; Figure 3). Conversely, the porcine implantation 
rate forms an n-shape, peaking in 2007-8. Volume has generally been increasing annually. 
In-hospital mortality 
There were 764 (3.1%) and 406 (3.0%) in-hospital deaths in the bovine pericardial and 
porcine groups respectively, which was not statistically significantly different (P = 0.806).  
Survival 
Follow-up data was tracked up until 30th July 2013. A total of 666 patients (1.8% records; 
511 bovine pericardial, 155 porcine) did not have post-discharge follow-up; however, they are 
included in the analysis by censoring them at the point of discharge. The median follow-up time was 
3.6 years (ranging from 0.5 days to 10.3 years). There were a total of 8731 deaths during follow-up 
(5652 bovine pericardial, 3079 porcine), but no statistically significant difference in survival (P = 
0.767; Figure 4; top panel). Survival at 1-, 5- and 8-years was 92.2%, 77.0% and 61.3% respectively 
in the bovine pericardial group, and 92.1%, 77.0% and 61.8% respectively in the porcine group. 
Survival at 10-years was 49.0% in the bovine pericardial group and 50.3% in the porcine group, 
however there were only 354 patients (<1%) at risk at this time point. 
For regression model development, pulmonary hypertension was removed as it yielded a 
counterintuitive coefficient and was highly non-significant. NYHA grades I and II were combined 
into a single reference group for dyspnoea, and stenosis and mixed lesions were combined into a 
single reference group for haemodynamics. The adjusted hazard ratio for porcine valve implantation 
was 0.98 [95% CI 0.93 – 1.03] (P = 0.41; Table 3).  
Intervention-free survival 
Of the 38,040 first-time cardiac surgery patients who had an AVR ± CABG, 387 (1.0%) had a 
re-intervention during the follow-up. Of the 387 patients, 376 (97.1%) had a single re-intervention and 
11 (2.8%) had two re-interventions. For the composite endpoint of mortality or re-intervention, there 
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were a total of 9002 events during follow-up (5817 bovine pericardial, 3185 porcine), but no 
statistically significant difference in survival (P = 0.97; Figure 4; bottom panel). Intervention-free 
survival at 1-, 5- and 8-years was 92.0%, 76.4% and 60.2% respectively in the bovine pericardial 
group, and 91.8%, 76.2% and 60.6% respectively in the porcine group. At 10-years the intervention-
free survival was 47.4% and 49.4% in the bovine pericardial and porcine groups respectively. The 
adjusted hazard ratio for porcine valve implantation was 0.98 [95% CI 0.94 – 1.03] (P = 0.50). 
Subgroup analyses 
Data on valve size was missing in 0.9% (329 / 38,040) of records and were imputed as part of 
the data imputation algorithm. The mean valve size in the bovine pericardial and porcine groups was 
22.6 ± 2.2 mm and 23.1 ± 2.2 mm respectively for the first imputed dataset (standardised difference -
21.8%; t-test P < 0.001). There were 14,189 valves (9937 [70.0%] bovine pericardial, 4252 [30.0%] 
porcine) in the first imputed dataset with a valve size ≤21 mm. Note that this number will slightly 
change with each imputed dataset. There was a statistically significant difference in mid-term 
intervention-free survival when comparing the 4 groups: bovine pericardial ≤21 mm; bovine 
pericardial >21 mm; porcine ≤21 mm; and porcine > 21 mm (P < 0.001; Figure 5; top panel). When 
comparing bovine pericardial to porcine valves in only the subset of valve sizes of ≤21 mm, there was 
no significant difference (P = 0.52). The pooled hazard ratio in favour of porcine valve implantation 
was 0.97 [95% CI 0.90 – 1.05] (P = 0.43), rejecting the null hypothesis of a difference in intervention-
free survival as a result of active selection of a higher gradient.  
There were 2084 patients aged <60 years at time of surgery (68.4% bovine pericardial; 31.6% 
porcine) and 35,956 patients aged ≥60 years (64.7% bovine pericardial; 35.3% porcine), giving a 
standardised difference of 3.7%. There was a statistically significant difference in mid-term 
intervention-free survival when comparing the 4 groups: bovine pericardial <60	years; bovine 
pericardial ≥60 years; porcine <60	years; and porcine ≥60 years (P < 0.001; Figure 5; bottom panel). 
Although no difference between valves in the ≥60 years old group (P = 0.87), there was some 
indication of a protective effect in the porcine valves for the <60 years old group (P = 0.055). It was 
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found that in this relatively younger group of patients, the bovine group was on average 1-year older 
(51.7 vs. 50.6; standardised difference 11.7%); had a higher prevalence of diabetes (13.5% vs. 9.9%; 
standardised difference 11.2%); and had a higher prevalence of pulmonary hypertension (1.3% vs. 
0.3%; standardised difference 10.9%). Adjusting for these potential confounding variables, in addition 
to selected other variables (gender, operative urgency, NYHA class, creatinine >200µmol/l, left 
ventricular ejection fraction; concomitant CABG and active infective endocarditis) and surgeon 
effects, the adjusted hazard ratio pooled over all imputed datasets was 0.78 [95% CI 0.60 – 1.02] (P = 
0.075) 
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DISCUSSION 
Principal findings 
This study shows no difference in survival or intervention free-survival between a large group 
of patients who had either a bovine pericardial or porcine tissue valve implanted in the aortic position 
between 2003 and 2013. Despite previously published evidence on the haemodynamic benefits of 
bovine pericardial valves as well as biological properties, these do not translate into better 
survival.3,10,11 There is no difference in survival between valve types in patients with a small 
prosthesis (≤21 mm), in whom difference in gradient between the valve types would be most marked. 
There was some evidence of better long-term intervention-free survival for the porcine valve in the 
relatively younger patient group (<60 years old), however this did not attain statistical significance.  
Comparison to other studies 
Reichenspurner et al. examined 1123 bioprostheses (4 bovine pericardial models and 4 
porcine models) over a 12-year study window in the aortic (67% of implants), mitral and tricuspid 
position.12 They reported a statistically significant (P < 0.05) difference in mid-term survival; at 10-
years survival was 61.0% (bovine pericardial) and 67.8% (porcine). However, this study represented 
operations between 1978 and 1990, including a number of first generation valves no longer in 
commercial use. Dalmau et al. randomised 108 patients undergoing AVR between 2004 and 2006 to 
receive either Edwards Lifesciences Perimount Magna (bovine pericardial) or Medtronic Mosaic 
(porcine) implants.13 They reported survival at 5 years to be 94.4% (bovine pericardial) and 79.6% 
(porcine), which was statistically significant (P = 0.039). They postulated that this difference might be 
attributable to favourable haemodynamics and improved left ventricular hypertrophy regression. This 
contrasts with our study where we have seen no difference in survival between porcine and bovine 
pericardial valves at 10-years of follow-up. Our study includes a heterogeneous group of both bovine 
pericardial and porcine valves, and whilst it does not preclude adverse or indeed superior outcomes in 
specific model types, it does show the ‘class’ of tissue valve, per se, does not affect survival.  
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We found no evidence of selection bias, as measured by the standardised difference. 
Therefore, the clinical hypothesis that bovine pericardial valves might be selected for females, who 
are more likely to have small aortic roots, is not irrefutably supported (standardised difference 5.6%), 
despite being significantly different (P < 0.001). Interestingly though, this was one of largest 
standardised differences, with a increase of 2.7 percentage points in female prevalence for bovine 
pericardial valves. Of interest there was no difference in the incidence of poor left ventricular function 
between the groups, indicating that surgeons are not in general using this, and the need for better 
haemodynamics in these patients, as a decision criterion for bovine pericardial valves. After adjusting 
for other patient characteristics and surgeon effects, choice of valve type was not associated with a 
difference in survival or intervention-free survival.  
Limitations 
This study was based on a national registry that has been collected over many years. 
Observational ‘real world’ data routinely has inaccuracies and this registry is no exception. However, 
there has been extensive validation of the data undertaken after submission and analysis by the units 
and surgeons submitting data as part of the UK cardiac surgery governance programme. Extensive on-
going data cleaning algorithms were applied to the registry before analysis. Another common 
limitation of large clinical registries is missing data. The numbers of missing data were relatively 
small in this study; however a few variables did have a large number of missing data. To overcome 
this we incorporated multiple imputation, which is a robust method for imputation that also takes into 
account the additional element of uncertainty.  
The National Adult Cardiac Surgery Audit registry does not feature predefined valves for 
selection in completing valve surgery data. Many hospitals have used a specific coding system or 
homogenous set of models and some allow free-text by the individual surgeons. This has inevitably 
led to an increase in data inconsistencies and missing data. A total of 5295 (12.0%) records were 
excluded due to missing data, unidentified coding, conflicts or unknown xenograft type. This situation 
is expected to improve in the future due to increased scrutiny on healthcare device monitoring.  
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Our definition of re-intervention was any surgery on the aortic valve performed up to 31st 
March 2013 in a separate subsequent admission spell. A limitation of this is that re-interventions 
performed between 1st April 2013 and 30th July 2013 (the date of census for mortality tracking) were 
not included; hence it is possible that the intervention-free survival rates have been slightly 
underestimated. Re-intervention was determined by identifying patients in the study according to their 
NHS number who reappeared in the NACSA registry. The NHS number was missing for 1524 
patients (4.0%), which required us to track these patients using their patient-hospital number. If these 
patients have a re-intervention elsewhere, it might not have been properly counted. Finally, a re-
intervention only included surgical aortic valve procedures. Transcatheter aortic valve implantation 
has been increasingly used in the United Kingdom in the latter half of this study window; however 
they are recorded in a separate registry and are therefore not included in the re-intervention rate.14 We 
do not believe that any of these limitations could significantly affect the overall findings. 
The classification of valves into bovine pericardial and porcine valves masks intra-class 
variation between models. Numerous studies have compared specific valve types, both within and 
between xenograft types.11–13,15 Specific valve properties such as stented or stentless mounting might 
also be associated differently within each xenograft type.16 The focus of this study is purely on the 
xenograft type. Although the focus of this study was on xenograft type, future work may involve 
assessing differences between different valve models. 
Although this study recorded results out to a maximum of 10.3 years, the median follow-up 
time was only 3.6 years. It would be expected that differences would manifest beyond this time 
interval, thus requiring longer follow-up. Moreover, we do not have data on cause of death, which 
would be beneficial for learning whether death was due to SVD.  
Meaning of study 
A number of studies have shown better haemodynamic performance in the bovine pericardial 
valves than compared to porcine valves.3,13,17–19 It might be extrapolated that better haemodynamics 
will translate into more rapid and complete regression of left ventricular modelling with better 
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survival. On the other hand, some studies have shown either superior haemodynamic performance or 
no-difference in the porcine group compared to the bovine pericardial group.20,21  
The differential haemodynamics are most marked in small prosthesis size, and as a sensitivity 
analysis we have repeated our study including only valves with recorded sizes of ≤21 mm and found 
no change in conclusions. On the basis of these findings there would seem to be clinical equipoise 
between porcine and bovine pericardial valves. It was previously believed that porcine valves should 
not be used in younger patients.22,23 However, more recent studies have shown that at 20-years, the 
performance in the Hancock II porcine valve is excellent and superior to that of the Edwards 
Lifesciences Perimount valve in younger patients.24,25 We found that there was a trend towards 
increased intervention-free survival in the porcine valve group compared to the bovine pericardial 
group; however, this did not reach statistical significance. 
Conclusion 
Over 10-years follow-up (with a median follow-up time of 3.6 years), there is no statistically 
significant difference in the performance of bovine pericardial and porcine bioprostheses implanted 
into first-time cardiac patients undergoing AVR ± CABG. Follow-up beyond 10-years is required as 
part of continuous monitoring and other endpoints should be monitored post-operatively including 
non-surgical re-intervention, functional class and haemodynamics.3 We have not analysed the data for 
specific model type within the general bovine pericardial / porcine classes, and it remains possible 
that specific valve models may be associated with different survival characteristics.  
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Figure 1. Flowchart describing patient numbers. 
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Figure 2. Total AVR ± CABG volume against bovine pericardial prosthesis implantation rate over the 
10-years. Each point represents a distinct cardiac surgeon. 
 
  
24	
	
Figure 3. Time trend of bovine pericardial valve implantation rate. The size of the points is 
proportional to the total number of AVR ± CABG procedures included in the study each year. 
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Figure 4. Kaplan-Meier curves stratified by valve type for survival (top panel) and intervention-free 
survival (bottom panel). 
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Figure 5. Kaplan-Meier curves stratified by valve type and (i) dichotomised valve size (top panel); 
(ii) dichotomised age at operation (bottom panel). 
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Table 1. Number of bioprostheses implanted over the study period. 
Bovine pericardial  (N = 24,695) 
Edwards Lifesciences Perimount 2700 31 
 Perimount 2900 6062 
 Perimount (unidentified sub-model) 3193 
 Perimount Magna 3000 3496 
 Perimount Magna with Thermafix 3000TFX 617 
 Perimount Magna Ease 3300TFX 5509 
 Perimount Magna (unidentified sub-model) 1110 
 Intuity 8300 1 
 Unknown 1 
Sorin Group Freedom Solo 158 
 Pericarbon Freedom 284 
 Soprano Armonia 353 
 Perceval S 11 
 Mitroflow # 2973 
 Unknown 4 
St Jude Medical Trifecta 892 
Porcine  (N = 13,345) 
Edwards Lifesciences Aortic Valve 2625 875 
 Supra-annular Aortic Valve 2650 588 
 Prima Plus Stentless 2500P 52 
St Jude Medical Epic Valve 2445 
 Epic Supra Valve 1918 
 Toronto Stentless Porcine Valve 14 
 Biocor valve 67 
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Medtronic Freestyle Stentless 127 
 Hancock II 2531 
 Mosaic 3534 
Vascutek* Elan 109 
 Aspire 1085 
* Includes the same valves under the holdings of Tissuemed, Kohler and Aortech.  
# Includes different generations (12A, LXA and DLA) 
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Table 2. Patient characteristics for the first imputed dataset stratified by aortic valve type. 
 Bovine pericardial 
(N = 24,695) 
Porcine 
(N = 13,345) 
Standardised 
difference 
P 
 Mean SD Mean SD 
Logistic EuroSCORE (%) 8.5 7.7 8.2 7.1 3.7 0.003 
Age (years) 73.2 8.6 73.7 8.5 -5.8 <0.001 
BMI 28.0 5.0 28.0 4.9 1.0 0.342 
 N % N %   
Female 9687 39.2 4870 36.5 5.6 <0.001 
Urgent 5777 23.4 2950 22.1 3.1 0.005 
Dyspnoea      0.003 
    NYHA I 3620 14.7 1970 14.8 -0.3  
    NYHA II 9738 39.4 5500 41.2 -3.6  
    NYHA III 9742 39.4 5039 37.8 3.5  
    NYHA IV 1595 6.5 836 6.3 0.8  
History of neurological dysfunction 684 2.8 337 2.5 1.5 0.169 
Diabetes 4600 18.6 2444 18.3 0.8 0.461 
History of hypertension 16,378 66.3 8853 66.3 0.0 0.980 
Pulmonary hypertension 427 1.7 172 1.3 3.6 0.001 
Recent MI 1647 6.7 848 6.4 1.3 0.245 
Creatinine >200 µmol/l 517 2.1 276 2.1 0.2 0.899 
History of pulmonary disease 4038 16.4 2031 15.2 3.1 0.004 
Extracardiac arteriopathy 2588 10.5 1242 9.3 3.9 <0.001 
Left ventricular function      0.044 
    LVEF >50% 17,926 72.6 9843 73.8 -2.6  
    LVEF 30-50% 5327 21.6 2741 20.5 2.5  
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    LVEF < 30% 1442 5.8 761 5.7 0.6  
Preoperative IV nitrates or heparin 
for treatment of unstable angina 
490 2.0 192 1.4 4.2 <0.001 
Critical preoperative state 488 2.0 189 1.4 4.3 <0.001 
Concomitant CABG 11,481 46.5 6189 46.4 0.2 0.840 
Haemodynamics      0.049 
    Stenosis 18,689 75.7 10,018 75.1 1.4  
    Regurgitation 1845 7.5 954 7.1 1.2  
    Mixed 4161 16.8 2373 17.8 -2.5  
Active infective endocarditis 230 0.9 116 0.9 0.7 0.581 
Abbreviations: BMI – body mass index; MI – myocardial infraction; LVEF – left ventricular ejection 
fraction; IV – intravenous; CABG – coronary artery bypass graft. 
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Table 3. Pooled results of Cox proportional hazards frailty regression models for mid-term survival 
fitted separately to each of five multiple imputed datasets. 
 HR 95% CI P-value 
Porcine valve 0.980 0.933 - 1.029 0.414 
Age (years) 1.006 0.997 - 1.015 0.207 
(Age - 65)+ (years) 1.066 1.055 - 1.078 <0.001 
BMI (kg / m2) 0.863 0.840 - 0.888 <0.001 
BMI2 (kg / m2)2 1.002 1.002 - 1.003 <0.001 
Female 0.896 0.856 - 0.938 <0.001 
Urgent 1.175 1.115 - 1.238 <0.001 
NYHA III 1.241 1.184 - 1.301 <0.001 
NYHA IV 1.422 1.312 - 1.540 <0.001 
History of neurological dysfunction 1.153 1.023 - 1.300 0.020 
Diabetes 1.322 1.251 - 1.396 <0.001 
History of hypertension 1.047 0.998 - 1.097 0.060 
Recent MI 1.035 0.954 - 1.123 0.406 
Creatinine >200 µmol/l 2.136 1.929 - 2.365 <0.001 
History of pulmonary disease 1.364 1.293 - 1.440 <0.001 
Extracardiac arteriopathy 1.293 1.214 - 1.377 <0.001 
LVEF 30-50% 1.293 1.230 - 1.361 <0.001 
LVEF <30% 1.662 1.534 - 1.801 <0.001 
Critical preoperative state 1.232 1.073 - 1.415 0.003 
Preoperative IV nitrates 1.135 0.987 - 1.306 0.077 
Concomitant CABG 1.201 1.148 - 1.257 <0.001 
Regurgitation 1.092 0.995 - 1.199 0.062 
Active infective endocarditis 1.303 1.043 - 1.628 0.020 
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Abbreviations: HR – hazard ratio; CI – confidence interval; BMI – body mass index; MI – 
myocardial infraction; LVEF – left ventricular ejection fraction; IV – intravenous; CABG – coronary 
artery bypass graft. (Age - 65)+ denotes 1 year for every year aged above 65 years; e.g. if age was 75, 
then (75 - 65)+ = 10; if age = 55, then (55 - 65)+ = 0.	Mean value of θ was 0.12 (2 d.p.). 
 
